Patents by Inventor Paul Alhadeff

Paul Alhadeff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATION
    Publication number: 20230181480
    Abstract: The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
    Type: Application
    Filed: January 6, 2023
    Publication date: June 15, 2023
    Inventors: Paul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
  • Formulation
    Patent number: 11596608
    Abstract: The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 7, 2023
    Assignee: Index Pharmaceuticals AB
    Inventors: Paul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
  • FORMULATION
    Publication number: 20210338592
    Abstract: The present invention relates a formulation and capsule suitable for oral administration. The invention further relates to the use of the formulation and capsule for treating inflammatory bowel diseases, for instance ulcerative colitis (UC) or Crohn's disease.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 4, 2021
    Inventors: Paul Alhadeff, Christine Dieterich Johansson, Peter Zerhouni, Wei Tian, Graeme William Andrew Hamilton Johnston
  • Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
    Patent number: 11123351
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: September 21, 2021
    Assignee: Umecrine Cognition AB
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • PHARMACEUTICAL FORMULATION OF 3-ALPHA-ETHYNYL-3-BETA-HYDROXYANDROSTAN-17-ONE OXIME
    Publication number: 20200297737
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Application
    Filed: February 21, 2020
    Publication date: September 24, 2020
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • Pharmaceutical formulation of 3?-ethynyl-3?-hydroxyandrostan-17-one oxime
    Patent number: 10603326
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: March 31, 2020
    Assignee: Umecrine Cognition AB
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • PHARMACEUTICAL FORMULATION OF 3ALPHA -ETHYNYL-3BETA-HYDROXYANDROSTAN-17-ONE OXIME
    Publication number: 20190358244
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Application
    Filed: June 24, 2019
    Publication date: November 28, 2019
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper